Potential Revenue:
" Easton Pharmaceuticals recently announced its agreement to invest and acquire an ownership interest in AMFIL Technologies Inc. and the mPACT-Grozone Antimicrobial Systems Line of Products. The Grozone product line, which includes the mPACT 60 unit, can be customized to fit the needs of small, medium and large medical marijuana growing facilities as well as other types of industries and applications. Once the unit's efficacy is validated at one location, the necessity for additional integrated units throughout the cultivation areas should be secured."
Potential Revenue:
"Easton Pharmaceuticals Inc. announces that as per updates it has received, site facility build-out as mandated per health Canada MMPR guidelines are near completion and soon ready for the scheduling of a new inspection on MMJ property where Easton holds exclusive option to purchase up to 50% ownership interest in private MMPR medical marijuana grower located in Ontario, Canada."
Potential Revenue:
"A counter proposal has been submitted to UMED where both companies would form a 50/50 joint partnership for new dispensaries with Easton paying the fees and expenses required to open the facilities and UMED finding the locations, design, launch the facilities, locate the product and patients for the dispensary. Discussions have also involved a direct investment into UMED for expansion of their existing business which after 6 months of operations with their own dispensary, revenues according to UMED are projected to conservatively reach $1 Million at the current pace with cumulative increases projected over the next few years."
Potential Revenue:
"As previously disclosed, Easton has engaged and announced that BMV Medica S.A. de C.V. has been appointed as its sole exclusive distributor in Mexico. BMV has signed an agreement with Easton on utilizing its resources and relationships aimed at marketing Viorra successfully in a market that BMV believes can be positioned as a leading-edge daily-use woman's health product to also assist in the treatment of FSAD type conditions. Easton has given BMV its approval to launch certain initiatives once manufacturing has been set up in Mexico, currently being addressed by BMV, which when complete, could also supply the United States, Canadian and International markets."
